CATERPILLAR™ Arterial Embolization Device Study

Embolization, Therapeutic Clinical Trial

— CHRYSALIS  

Official title:

A Prospective, Multi-Center, Single-Arm Study Assessing the Clinical Use of the CATERPILLAR™ Arterial Embolization Device System for Arterial Embolization in the Peripheral Vasculature (CHRYSALIS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04090320
• Other study ID #: BPV-16-002
• Status: Completed
• Phase: N/A
• Start date: September 25, 2019
• Est. completion date: November 4, 2020

Study information

• Verified date: January 2021
• Source: C. R. Bard
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the performance and safety of the CATERPILLAR™ Arterial Embolization Device when used for arterial embolization in the peripheral vasculature.

Description:

This feasibility study is a prospective, multi-center, single-arm study of the CATERPILLAR™ Arterial Embolization Device. Up to twenty (20) subjects will be treated with the CATERPILLAR™ Arterial Embolization Device at up to 5 investigational sites in New Zealand and Australia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 4, 2020
• Est. primary completion date: November 4, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Clinical Inclusion Criteria:

1. Subject must voluntarily sign and date the approved Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.

2. Subject must be either male or non-pregnant female =18 years of age with an expected lifespan sufficient to allow for completion of all study procedures.

3. Subject must be willing and able to comply with protocol requirements, including all study visits and procedures.

4. Subject must require peripheral vascular occlusion at an arterial target embolization site(s) that can be treated with the CATERPILLAR™ Arterial Embolization Device according to the Instructions for Use (IFU). Note: More than one target embolization site may be treated per subject.

Angiographic Inclusion Criteria:

5. The target embolization site(s) must be located in a native arterial vessel(s) with the intended arterial vessel diameter ranges shown in the IFU, as assessed by the Investigator (via visual estimate).

6. The target embolization site(s) must have a landing zone sufficient to accommodate the device implant lengths shown in the IFU.

Clinical Exclusion Criteria:

1. The subject's access vessel(s) preclude safe insertion of the delivery catheter.

2. The subject's target embolization site(s) is located within a vein.

3. The subject's target embolization site(s) is located within the head, neck, heart or coronary vessels.

4. The subject's target embolization site(s) is located across highly locomotive joints or muscle beds (e.g. elbow, hip, knee, shoulder, thoracic inlet/outlet).

5. The subject's target embolization site(s) is located in a high-flow vessel where, in the opinion of the Investigator, there may be significant risk of migration and unintended (non-target site) occlusion.

6. The subject has a known allergy or hypersensitivity to contrast media that cannot be adequately pre-medicated.

7. The subject has a known allergy or hypersensitivity to any of the device materials including: cobalt, chromium, nickel, titanium, platinum, iridium, polyurethane or polyethylene.

8. The subject will receive anticoagulant or antiplatelet therapy (e.g. direct thrombin inhibitors, factor Xa inhibitors, vitamin K antagonists) before, during and/or after treatment with the study device, which, in the opinion of the Investigator, would clinically interfere with the study endpoints.

9. The subject has a known uncontrolled blood coagulation or bleeding disorder.

10. The subject has an unresolved systemic infection.

11. The subject's required pre-operative laboratory tests and/or physical examination indicate abnormal results, which, in the opinion of the Investigator, would clinically interfere with the study endpoints.

12. The subject has a connective tissue disorders (e.g. Ehlers-Danlos Syndrome), arteritis (e.g. Takayasu's Disease) or another circulatory disorder, which, in the opinion of the Investigator, would clinically interfere with the study endpoints.

13. The subject has another medical condition which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, may confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.

14. The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.

Related Conditions & MeSH terms

• Embolization, Therapeutic

Intervention

Device:
• CATERPILLAR™ Arterial Embolization Device
Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.

Locations

Country	Name	City	State
Australia	Sydney Local Health District	Camperdown	New South Wales
Australia	Alfred Health	Melbourne	Victoria
Australia	Royal Perth Hospital	Perth	Western Australia
New Zealand	Auckland Hospital	Auckland
New Zealand	Clinical Trials New Zealand	Hamilton

Sponsors (1)

Lead Sponsor	Collaborator
C. R. Bard

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Technical Success	Technical Success: Successful occlusion of the target embolization site(s) as confirmed by the Investigator via angiographic assessment during the Index Procedure. Technical success will be reported for each target embolization site.	Index Procedure.
Primary	Freedom from Device-Related SAEs	Freedom from Device-Related Serious Adverse Events (SAE) through 30 day follow-up.	30 (-7/+21) Days
Secondary	Time Point of Occlusion	The percentage of target embolization site(s) with occlusion at =1, =2, =3, =4, =5, =10 and >10 minutes post-treatment.	Index Procedure
Secondary	Freedom from Recanalization	Freedom from clinically relevant recanalization of the target embolization site(s) through 30 day follow-up as confirmed by the Investigator. Clinically relevant recanalization is defined as recanalization through the study device that requires a re-intervention. Freedom from recanalization will be reported for each target embolization site.	30 (-7/+21) Days
Secondary	Freedom from Migration	Freedom from Migration will be reported for each study device as follows: Freedom from clinically relevant acute migration of the study device(s) as confirmed by the Investigator via angiographic assessment during the Index Procedure. Clinically relevant migration is defined as migration of the study device from the target embolization site that requires intervention.; Freedom from clinically relevant migration of the study device(s) through 30 day follow-up as confirmed by the Investigator. Clinically relevant migration is defined as migration of the study device from the target embolization site that requires a re-intervention.	30 (-7/+21) Days
Secondary	Freedom from Device and/or Procedure-Related Adverse Events	Freedom from device and/or procedure-related adverse events (AE) through 30 day follow-up.	30 (-7/+21) Days
Secondary	Investigator Satisfaction	The following will be reported by Investigators for each study device during the Index Procedure: Accurate delivery of the CATERPILLAR™ Arterial Embolization Device to the target embolization site; Ease of CATERPILLAR™ Arterial Embolization Device trackability and deliverability; Acceptability of CATERPILLAR™ Arterial Embolization Device visibility under fluoroscopy	Index Procedure